

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/678,167	10/06/2003	Francine Goulet	238813US-6 DIV	5723
28291	7590 08/01/2005		EXAM	INER
	ONHAUGH - SMAR	PRONE, CHRISTOPHER D		
	GAUCHETIERE WEST		ART UNIT	PAPER NUMBER
SUITE 3300			ARTONII	PAPER NOMBER
MONTREAL, QC H3B 4W5			3738	
CANADA				_

**DATE MAILED: 08/01/2005** 

Please find below and/or attached an Office communication concerning this application or proceeding.

		<u> </u>			
	Application No.	Applicant(s)			
	10/678,167	GOULET ET AL.			
Office Action Summary	Examiner	Art Unit			
	Christopher D. Prone	3738			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above, the maximum statutory period  - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailine earned patent term adjustment. See 37 CFR 1.704(b).		nely filed  s will be considered timely. If the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 19.	July 2005.				
· · · · · · · · · · · · · · · · · · ·	<u> </u>				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the ments is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims		•			
4) ☐ Claim(s) 25-52 is/are pending in the application 4a) Of the above claim(s) is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 25-52 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/	awn from consideration.				
Application Papers		·			
9)☐ The specification is objected to by the Examin	er.	,			
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11)☐ The oath or declaration is objected to by the E	Examiner. Note the attached Office	e Action or form PTO-152.			
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
Attachment(s)					
1) Notice of References Cited (PTO-892)	4) Interview Summary Paper No(s)/Mail D				
<ul> <li>2) Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date</li> </ul>		Patent Application (PTO-152)			

Application/Control Number: 10/678,167

Art Unit: 3738

#### **DETAILED ACTION**

### Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 4/25/05 has been entered.

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) The invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 25-52 are rejected under 35 U.S.C. 102(e) as being anticipated by Altman (USPN 6,287,340 B1).

Altman discloses the method for preparing an implant *ex vivo* for connective tissue substitution (specifically ACL) comprising the steps of providing a pair of bone anchors composed of coral or bone (abstract) and attaching these bone anchors by a support filament composed of a cylindrical 3-dimensional matrix formed of collagen gel

Application/Control Number: 10/678,167

Art Unit: 3738

(2:20-39). The matrix is seeded with stem cells or bone marrow stromal cells and subjected to mechanical forces (2:19-65). Osteoblast cells may be selected from a bovine species (13:62-14:22). The cells were mixed with an antibiotic, i.e. penicillin, and other pharmaceutical compounds to form the cell medium (14:36-52). The matrix and the bone anchor are coated with materials such as laminin, fibronectin, or factors containing arginine-glycine-aspartate peptides that produce enhanced bone and matrix attachment. After the incubation period fibronectin was found in the matrix layer (13:17-39). The substitute is used for connective tissue such as a tendon, cartilage or muscle. After the cells are seeded to the matrix the matrix is attached to the bone anchors and placed into a bioreactor where it undergoes the application of forces to simulate the forces that would be experienced *in vivo*.

#### Response to Arguments

Applicant's arguments filed 4/25/05 have been fully considered but they are not persuasive. The new amendments to the claims do not place the application in condition for allowance because: Contrary to Applicant's arguments, Altman does disclose laminin or fibrin that is sufficient thickness to allow for colonization by a cell. Applicant discloses in paragraph [0027] that their matrix is equivalent to a network of materials such as laminin or fibronectin. Applicant has not disclosed a specific thickness that is sufficient for colonization of cells therefore it is Inherent that the matrix of Altman is capable of performing the function as claimed by the Applicant. Altman also discloses that the matrix undergoes a dehydration or lyophilization process before Implantation. Altman

Application/Control Number: 10/678,167

Art Unit: 3738

X.

The Applicant's arguments are unpersuasive.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Christopher D. Prone whose telephone number is (571)

specifically discloses a "dehydrothermal" process that includes dehydration (5:1-10).

272-6085. The examiner can normally be reached on Monday Through Fri 8:30 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Corrine McDermott can be reached on (571) 272-4754. The fax phone

number for the organization where this application or proceeding is assigned is 703-

872-9306.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

Christopher D Prone

Examiner

Art Unit 3738

*op* CDP

> CORRINE McDERMOTT SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER "